M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Pierpaolo Correale,Cirino Botta,Assunta Basile,Marco Pagliuchi,Antonella Licchetta,Ignazio Martellucci,Elena Bestoso,Serena Apollinari,Raffaele Addeo,Gabriella Misso,Ornella Romano,Alberto Abbruzzese,Monica Lamberti,Luca Luzzi,Giuseppe Gotti,Maria Saveria Rotundo,Michele Caraglia,Pierosandro Tagliaferri +17 more
TL;DR: A phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen of bevacizumab in combination with erlotinib and the toxicity associated with the treatment requires strict selection of the patients to enroll in future studies.
Journal ArticleDOI
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Oriana Lo Re,Concetta Panebianco,Stefania Porto,Carlo Cervi,Francesca Rappa,Stefano Di Biase,Michele Caraglia,Valerio Pazienza,Manlio Vinciguerra +8 more
TL;DR: Fasting or fasting‐mimicking diet diets should be evaluated in preclinical studies as a mean to potentiate the activity of Sorafenib in clinical use.
Journal ArticleDOI
Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
Michele Caraglia,G. De Rosa,Giuseppina Salzano,Daniele Santini,Monica Lamberti,Pasquale Sperlongano,Angela Lombardi,Alberto Abbruzzese,Raffaele Addeo +8 more
TL;DR: This review summarizes the most meaningful advances in the field of nanotechnologies for brain delivery of drugs.
Journal ArticleDOI
Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL).
Raffaele Addeo,Michele Caraglia,Alfonso Baldi,D'Angelo,Fiorina Casale,Stefania Crisci,Alberto Abbruzzese,Vincenze B,Mara Campioni,Di Tullio Mt,Paolo Indolfi +10 more
TL;DR: P53 alterations were uncommon and alone not strong independent predictors of outcome, but they were correlated to poor response to therapy with PDN and inversely correlated to EFS and OS in univariate analysis.
Journal ArticleDOI
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases
Raffaele Addeo,Pasquale Sperlongano,Liliana Montella,Bruno Vincenzi,Marco Carraturo,Patrizia Iodice,Paola Russo,Ciro Parlato,Antonio Salzano,Gregorio Cennamo,Angela Lombardi,Rossella Sperlongano,Salvatore Del Prete,Michele Caraglia +13 more
TL;DR: In conclusion, the treatment was safe and a significant number of objective responses were observed with a significant improvement in quality of life demonstrated by FACT-B and a large randomized trial is warranted in BC patients with previously untreated BM.